A Phase 2 interventional study of lenvatinib and Tislelizumab in Advanced Solid Tumor, sponsored by BeiGene. Completed at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical trial evaluated the safety and potential benefits of combining two cancer treatments, tislelizumab and lenvatinib, in Chinese participants with advanced or metastatic cancers, including lung, head and neck, bladder, kidney, and stomach cancer. The study included two parts: the first part assessed how safe the drug combination was, and the second part examined how well it worked.
A small group of participants initially received the drugs to determine the appropriate dose, and if the treatment was well tolerated, additional participants were treated at that dose. Participants remained on the treatment unless their cancer progressed, they experienced serious side effects, or they chose to stop.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Participants had a and/or cytologically confirmed diagnosis of advanced solid tumors, which included one of the following types:
Key Exclusion Criteria:
Note: Additional protocol-defined inclusion and exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced or metastatic unresectable solid tumors were enrolled to receive 400 mg of tislelizumab administered on Day 1 of each 6-week cycle, along with 20 mg of lenvatinib self-administered orally once daily, to determine the recommended Part 2 dose (RP2D).
Drug: lenvatinib · Drug: Tislelizumab
Participants with previously untreated, advanced or metastatic SCCHN received tislelizumab (400 mg administered intravenously \[IV\] every 6 weeks \[Q6W\]) in combination with lenvatinib (20 mg taken orally once daily \[QD\]) until disease progression, start of new anticancer therapy, unacceptable toxicity, withdrawal of consent, or study termination.
Drug: lenvatinib · Drug: Tislelizumab
Systemic therapy naive participants with advanced or metastatic RCC received tislelizumab (400 mg IV Q6W) plus lenvatinib (20 mg orally QD) until disease progression, start of new anticancer therapy, unacceptable toxicity, withdrawal of consent, or study termination.
Drug: lenvatinib · Drug: Tislelizumab
Participants with NSCLC expressing programmed cell death-ligand 1 (PD-L1) in ≥1% of tumor cells (TC ≥1%) and who had not received prior systemic therapy received tislelizumab (400 mg IV Q6W) and lenvatinib (20 mg orally QD) until disease progression, start of new anticancer therapy, unacceptable toxicity, withdrawal of consent, or study termination; this cohort was closed early based on emerging external data.
Drug: lenvatinib · Drug: Tislelizumab
Participants with advanced GC who had received one prior line of systemic therapy were enrolled to receive tislelizumab and lenvatinib at the RP2D (tislelizumab 400 mg IV Q6W; lenvatinib 20 mg orally QD) until disease progression, start of new anticancer therapy, unacceptable toxicity, withdrawal of consent, or study termination; this cohort was closed early due to changes in the first-line standard of care.
Drug: lenvatinib · Drug: Tislelizumab
Participants with cisplatin ineligible, systemic therapy naive advanced UC, were to be treated with tislelizumab (400 mg IV Q6W) and lenvatinib (20 mg orally QD). This cohort was closed prior to any participant enrollment based on emerging external data.
Drug: lenvatinib · Drug: Tislelizumab
Administered at the dose of 20 mg orally, once daily.
400 mg administered intravenously on Day 1 of each 42-day cycle
Also known as: BGB-A317
Safety Run-in: Number of Participants With Adverse Events (AEs)
An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is related to the study drug. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement. A dose-limiting toxicity (DLT) was defined as a Grade 3 or 4 hematologic or nonhematologic toxicity occurring during the DLT assessment window and deemed related to one or more study drugs by the investigator.
Time frame: From first dose through the end of the safety run-in part, up to 124 days; The DLT observation period was 28 days after first dose.
Overall Response Rate (ORR)
Overall response rate is defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments. CR is defined as the disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Progression Free Survival (PFS)
PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Duration of Response (DOR)
DOR was defined as the time from the first documented objective response to documented radiological disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive disease is captured as at least a 20% increase in the sum of diameters of target lesions, using the smallest sum on study as the reference (including the baseline sum if it was the smallest). In addition to the 20% relative increase, the sum also had to show an absolute increase of at least 5 mm.
Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Disease Control Rate (DCR)
DCR was defined as the percentage of participants who demonstrated a confirmed complete response (CR), partial response (PR), or stable disease (SD) as the best overall response, in accordance with the RECIST version 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions with no new lesions observed. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum of diameters as the reference. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), using the smallest sum of diameters recorded while on study as the reference.
Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Overall Survival (OS)
OS was defined as the time from randomization to the documented date of death for participants who died on or before the data cutoff date. Median OS was calculated using the Kaplan-Meier method. Data for participants who were alive at the data cutoff date were censored at their last known alive date, defined as either the clinical cutoff date for those still on treatment or the most recent available date confirming they were alive, whichever occurred first.
Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Number of Participants Experiencing Adverse Events (AEs)
An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is related to the study drug.
Time frame: From first dose of study drug to 30 days after last dose, up to the study completion date of 10 July 2024 (up to 32.5 months)
Participants were enrolled in multiple study centers in China. The first participant dosed was on September 18th, 2021 and the last participant completed on July 10th, 2024. Enrollment began with a run-in phase to assess the safety and tolerability of tislelizumab plus lenvatinib combination therapy. Once the Safety Monitoring Committee confirmed that the combination therapy was tolerable, enrollment into the expansion phase began.
| Milestone | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| Started | 27 | 23 | 5 | 3 |
| Treated | 27 | 23 | 5 | 3 |
| Enrolled in safety run-in stage | 2 | 0 | 5 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 27 | 23 | 5 | 3 |
| Withdrew: Study completed by sponsor | 16 | 16 | 3 | 3 |
| Withdrew: Death | 11 | 6 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 |
| Withdrew: Miscellaneous. | 0 | 1 | 0 | 0 |
An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is related to the study drug. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement. A dose-limiting toxicity (DLT) was defined as a Grade 3 or 4 hematologic or nonhematologic toxicity occurring during the DLT assessment window and deemed related to one or more study drugs by the investigator.
| Participants | Safety Run-In |
|---|---|
| Number of Participants with any TEAEs | 6 |
| Number of Participants with any SAEs | 4 |
| Number of Participants with any DLTs | 0 |
Overall response rate is defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments. CR is defined as the disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| Safety Analysis Set | 29.6 (13.8 to 50.2) | 60.9 (38.5 to 80.3) | 20.0 (0.5 to 71.6) | 33.3 (0.8 to 90.6) |
| Evaluable Analysis Set | 33.3 (15.6 to 55.3) | 66.7 (43.0 to 85.4) | 20.0 (0.5 to 71.6) | 33.3 (0.8 to 90.6) |
PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
| Months | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 6.1 (4.3 to 13.7) | 15.4 (8.4 to NA) | 6.0 (2.5 to NA) | NA (1.4 to NA) |
DOR was defined as the time from the first documented objective response to documented radiological disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive disease is captured as at least a 20% increase in the sum of diameters of target lesions, using the smallest sum on study as the reference (including the baseline sum if it was the smallest). In addition to the 20% relative increase, the sum also had to show an absolute increase of at least 5 mm.
| Months | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| Duration of Response (DOR) | 9.6 (2.8 to NA) | NA (10.8 to NA) | 18.5 (NA to NA) | NA (NA to NA) |
DCR was defined as the percentage of participants who demonstrated a confirmed complete response (CR), partial response (PR), or stable disease (SD) as the best overall response, in accordance with the RECIST version 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions with no new lesions observed. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum of diameters as the reference. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), using the smallest sum of diameters recorded while on study as the reference.
| Percentage of Participants | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| Safety Analysis Set | 70.4 (49.8 to 86.2) | 87.0 (66.4 to 97.2) | 100.0 (47.8 to 100.0) | 66.7 (9.4 to 99.2) |
| Evaluable Analysis Set | 79.2 (57.8 to 92.9) | 95.2 (76.2 to 99.9) | 100.0 (47.8 to 100.0) | 66.7 (9.4 to 99.2) |
OS was defined as the time from randomization to the documented date of death for participants who died on or before the data cutoff date. Median OS was calculated using the Kaplan-Meier method. Data for participants who were alive at the data cutoff date were censored at their last known alive date, defined as either the clinical cutoff date for those still on treatment or the most recent available date confirming they were alive, whichever occurred first.
| Month | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| Overall Survival (OS) | NA (5.7 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is related to the study drug.
| Participants | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| Number of Participants with any TEAEs | 27 | 22 | 5 | 3 |
| Number of Participants with any SAEs | 17 | 11 | 2 | 2 |
Collected over All-cause mortality data were collected from randomization through the end of the study (up to 34 months). Serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) were collected from the date of first study drug administration through 30 days after the last dose (up to 32.5 months).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Squamous Cell Carcinoma of the Head and Neck (SCCHN) | 11/27 (40.7%) | 17/27 (63%) | 27/27 (100%) |
| Renal Cell Carcinoma (RCC) | 6/23 (26.1%) | 11/23 (47.8%) | 21/23 (91.3%) |
| Non-Small Cell Lung Cancer (NSCLC) | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Gastric Cancer (GC) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| MyocarditisCardiac disorders | 0/27 | 0/23 | 0/5 | 1/3 |
| Alanine aminotransferase increasedInvestigations | 0/27 | 0/23 | 0/5 | 1/3 |
| Aspartate aminotransferase increasedInvestigations | 0/27 | 0/23 | 0/5 | 1/3 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/27 | 0/23 | 1/5 | 0/3 |
| ProteinuriaRenal and urinary disorders | 0/27 | 0/23 | 1/5 | 0/3 |
| PneumoniaInfections and infestations | 3/27 | 0/23 | 0/5 | 0/3 |
| Acute myocardial infarctionCardiac disorders | 0/27 | 2/23 | 0/5 | 0/3 |
| DeathGeneral disorders | 2/27 | 0/23 | 0/5 | 0/3 |
| COVID-19 pneumoniaInfections and infestations | 2/27 | 0/23 | 0/5 | 0/3 |
| Myocardial infarctionCardiac disorders | 0/27 | 1/23 | 0/5 | 0/3 |
| Event | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) |
|---|---|---|---|---|
| ProteinuriaRenal and urinary disorders | 7/27 | 6/23 | 5/5 | 1/3 |
| HypertensionVascular disorders | 16/27 | 15/23 | 4/5 | 1/3 |
| HypothyroidismEndocrine disorders | 10/27 | 16/23 | 3/5 | 1/3 |
| HypokalaemiaMetabolism and nutrition disorders | 1/27 | 3/23 | 0/5 | 2/3 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 7/27 | 9/23 | 3/5 | 0/3 |
| Weight decreasedInvestigations | 13/27 | 13/23 | 1/5 | 0/3 |
| COVID-19Infections and infestations | 4/27 | 10/23 | 0/5 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 5/27 | 5/23 | 2/5 | 0/3 |
| Upper respiratory tract infectionInfections and infestations | 1/27 | 0/23 | 2/5 | 0/3 |
| Platelet count decreasedInvestigations | 2/27 | 8/23 | 0/5 | 0/3 |
The Safety Analysis Set is defined as all participants who received ≥ 1 dose of study drug(s).
| Age, Continuous(years) | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) | Total |
|---|---|---|---|---|---|
| Mean | 61.9 ± 10.14 | 62.3 ± 7.38 | 65.6 ± 7.92 | 61.3 ± 9.29 | 62.3 ± 8.75 |
| Sex: Female, Male(Participants) | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) | Total |
|---|---|---|---|---|---|
| Female | 8 | 6 | 1 | 0 | 15 |
| Male | 19 | 17 | 4 | 3 | 43 |
| Race/Ethnicity, Customized(Participants) | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Renal Cell Carcinoma (RCC) | Non-Small Cell Lung Cancer (NSCLC) | Gastric Cancer (GC) | Total |
|---|---|---|---|---|---|
| Chinese | 27 | 23 | 5 | 3 | 58 |
| Other | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Sep 2021 to primary completion in Oct 2023, 25 months.
Results were first posted in Aug 2025, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab